Zeo ScientifiX Partnership with Pluri Inc.
Zeo ScientifiX entered into a definitive strategic agreement with Pluri Inc. to expand U.S. manufacturing and commercialization of regenerative medicine products. As part of the license-for-equity transaction, Pluri will grant ZEO an exclusive license to its proprietary 3D cell expansion platform in exchange for a 41% equity stake in ZEO and a share swap involving 4% of each company's outstanding stock.
- Counterparty
- Pluri Inc.